PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Abstract Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype...

Full description

Bibliographic Details
Main Authors: Francesco Cognetti, Riccardo Masetti, Alessandra Fabi, Giulia Bianchi, Donatella Santini, Alessia Rognone, Giovanna Catania, Domenico Angelucci, Giuseppe Naso, Mario Giuliano, Lucia Vassalli, Patrizia Vici, Giovanni Scognamiglio, Daniele Generali, Alberto Zambelli, Marco Colleoni, Corrado Tinterri, Francesco Scanzi, Leonardo Vigna, Paola Scavina, Teresa Gamucci, Emilia Marrazzo, Angelo Fedele Scinto, Rossana Berardi, Maria Agnese Fabbri, Graziella Pinotti, Daniela Franco, Daniela Andreina Terribile, Giuseppe Tonini, Daniela Cianniello, Sandro Barni
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-021-00246-4

Internet

https://doi.org/10.1038/s41523-021-00246-4

Similar Items